Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering

Parallel to the growing role of tissue engineering, the need for cell embedding materials, which allow cells to stabilise in a three-dimensional distribution, has increased. Although several substances have been tested, fibrin is thus far the only one that permits the clinical application of cultured tissue. To date, can cause severe immunological side effects. The objective of this study was to explore the practicability of obtaining autologous thrombin from a single patient in an adequate concentration and amount. Fibrinogen was cryoprecipitated from 200 ml of freshly-frozen plasma. Thrombin was isolated from the supernatant through ionexchange chromatography. The thrombin was first bound to Sephadex A-50 and then eluated using 2ml of a salt buffer (2.0M NaCl in 0.015M trisodiumcitrate, pH 7.0). The activity of the thrombin (51 NIH ml⁻¹ to 414 NIH ml⁻¹) reached levels comparable to those in commercially available fibrin glues (4–500 NIH ml⁻¹). The study has shown that it is possible to obtain a sufficient amount of autologous thrombin from a single donor to create a fibrin matrix of high efficiency without the risk of immunological and infectious side effects.     

Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases,years on from transplant

Current international guidelines recommend routinely vaccinating haematopoetic stem cell transplant (HSCT) recipients. Despite significant infection-related mortality following autologous HSCT, routine vaccination programmes (RVP) completion is poor. For recovered HSCT recipients, it is uncertain whether catch-up vaccination remains worthwhile years later.To determine potential susceptibility to vaccine preventable infections, we measured antibody titres in 56 patients, a median of 7 years (range 0–29) following autologous HSCT, who had not completed RVP. We found that almost all participants had inadequate titres against diphtheria (98.2%) and pneumococcal infection (100%), and a significant proportion had inadequate titres against measles (34.5%). Of those subsequently vaccinated according to available guidelines, many mounted adequate serological responses.These data suggest a pragmatic catch-up approach for autologous HSCT recipients who have not completed RVP is advisable, with universal vaccination against some pathogens (e.g. Streptococcus pneumoniae and diphtheria) and serologically-guided approaches for others (e.g. measles and varicella zoster virus).     

Predeposit Autologous Blood Donation: a survey of patient attitudes

Attitudes to autologous blood donation have been surveyed in a group of 38 postoperative bariatric patients. Only two patients (5%) declined to participate. Twenty-eight of 38 (70%) successfully predeposited autologous blood. Twenty-five of 28 donors (90%) had done so at the suggestion of their surgeon. Concern about contracting AIDS was the motivating factor in the majority of patients (21 patients, = 55%). Lack of infectious complications in general was cited by an additional four (11%). All respondents would donate autologous blood in the future, and would recommend the procedure to others who were about to undergo elective surgery. There was an increase from 29% to 50% who stated that, following their autologous donation experience, they would consider being homologous volunteer blood donors in the future.     

造血干细胞移植治疗恶性血液病疗效分析

 目的　比较自体与异体造血干细胞移植 (HSCT)治疗白血病和非霍杰金氏淋巴瘤 (NHL)的疗效和移植相关死亡。方法　 2 2 2例白血病和NHL中 ,112例接受自体HSCT、110例接受异体HSCT ,其中38例急性早幼粒细胞白血病 (M3 )和 36例NHL均为自体HSCT。移植预处理方案包括 :14 9例TBI +Cy、2 3例改良Bucy、5 0例MACC方案。 结果　全部患者均获得造血重建 ,在自体与异体移植后白细胞>1.0× 10 9/L和血小板 >2 0× 10 9/L的时间 ,二组分别为 (14 .3± 6 .1)d和 (17.8± 9.2 )d与 (15 .1±4 .6 )d和 (19.6± 10 .3)d ,二组比较造血重建时间无差异 (P >0 .0 1)。非M3 白血病自体与异体移植后 5年估计无病生存率为 (5 2 .0± 5 .8) %和 (6 2 .4± 6 .2 ) %、复发率为 (44 .7%和 14 .5 % ) ,M3 白血病自体移植无病生存率 (93.6± 4 .4 ) %、复发率 5 .3% ,NHL自体移植无病生存率 (6 6 .3± 8.0 ) %、复发率 2 2...     

In vitro evaluation study of the membrane autotransfusion system experimental prototype: MATS-I

Abstract: Membrane Autotransfusion System (MATS) utilizing plasmapheresis technology has been developed in our laboratory. A specially designed polyethylene hollow fiber membrane was utilized. This study was conducted to evaluate performance of the first experimental prototype, MATS-I. The results of this study showed that the MATS-I could concentrate diluted blood at 10% of the initial hematocrit concentration (HCTi) into over 40% after passing through the system at a transmembrane pressure of 70 mm Hg. Moreover, the MATS-I can continuously treat 10,000 ml of diluted blood at various HCTi levels without deteriorating its performances. Even though the MATS-I met all required performances as an autotransfusion system, several areas of improvement of the system were necessary to meet various clinical needs. The next prototype, MATS-II, can be designed based on experiences obtained from the MATS-I. The MATS is smaller, more atraumatic and continuous, and is a faster system when compared to the currently available centrifugal autotransfusion devices.     

自体造血干细胞移植治疗恶性血液病116例临床分析

目的：探讨自体造血干细胞移植（AHSCT）治疗恶性血液病的疗效及影响因素。方法：观察三种不同移植方法的并发症，造血恢复时间，三年无病生存率（DFS）。结果：自全外周血造血干细胞移植（APBSCT）并发症少，造血恢复快，但三种移植方法DFS无明显差别。结论：APBSCT较自体骨髓移植（ABMT）更安全，对于获得缓解者宜尽早施行移植治疗。     

恶性胸腹水自体蛋白的制备及回输

恶性肿瘤晚期患者常并发胸腹水，胸腹水里含有大量可溶性蛋白，蛋白浓度约为40mg／ml，其中白蛋白占50％以上，球蛋白占20％左右。本实验室比较了4种不同的分离纯化胸腹水蛋白的方法，其中离心滤过的方法能彻底除去细胞成分，特别是肿瘤细胞，而且蛋白回收率高，操作简单，不参入外源物质，我们采用该方法将恶性胸腹水中的蛋白回收，并回输给患者，临床应用27例次，取得了较好的临床效果。     

自体心包瓣“内皮化”的实验研究

目的 探讨有利于自体心包瓣内皮化的处理方法。方法 将体外培养小牛主动脉内皮细胞接种于不同方法处理的自体牛心包表面。采用＾３Ｈ－ＴｄＲ摄取量测定、扫描电镜及放射免疫法观察不同处理方法对接种后内皮细胞生长、前列环素（ＰＧＩ２）合成量和细胞内ｃＡＭＰ含量的影响。结果 三种不同浓度戊二醛短时间（１０ｍｉｎ）处理的心包表面内皮细胞均可生长,其中以体积分数为０．２％戊二种不同浓度戊二醛短时间（１０ｍｉｎ）处理     

Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM)

Background: Disease status before high-dose chemotherapy with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) is an important predictor of transplantation-related toxicity and event-free survival (EFS) for patients with relapsed or refractory Hodgkin's disease (HD). We performed a phase II study in patients with relapsed or refractory HD to evaluate the feasibility of four cycles of Dexa-BEAM followed by high-dose chemotherapy with ABMT or PBSCT.Patients and methods: Twenty-six patients (median age 30, range 20–40 years) were treated with 2–4 courses of dexamethasone, carmustine, etoposide, cytarabine and melphalan (Dexa-BEAM) as salvage chemotherapy in order to attain maximal response. Patients achieving complete response (CR) or partial response (PR) received high-dose chemotherapy with ABMT or PBSCT. The conditioning regimen used was CVB (cyclophosphamide, carmustine, etoposide).Results: Eighteen patients responded to Dexa-BEAM, resulting in a response rate of 69%. At the time of transplant 16 patients were in CR two patients in PR. At present 14 patients transplanted are in continous CR (median follow-up 40 months, range 14–60 months). Two patients with PR after four courses of Dexa-BEAM relapsed and died three months posttransplantation. Two patients with CR at the time of transplant relapsed after nine and 13 months respectively. Eight patients had rapid progressive disease after 2–4 cycles of Dexa-BEAM. One patient with progressive disease died in gram-negative sepsis after four cycles of Dexa-BEAM. There was no transplantation-related death.Conclusion: These data suggests the use of high-dose chemotherapy followed by stem cell transplantation at the time of maximal response.     

钢丝环固定自体表皮移植治疗白癜风

目的探索特殊部位白癜风自体表皮移植治疗的包扎固定方法。方法试验组移植区边缘用钢丝环绕一周,缝合固定于皮肤上,并留置长线,皮片移植后将包扎敷料打包固定。对照组包扎敷料用胶带封包。结果自体表皮移植治疗眼睑及唇部易活动部位白癜风,采用钢丝环固定包扎,术区护理方便,对正常生活影响小,其治疗效果与传统的包扎方法相比有效率有明显提高(P<0.01)。结论钢丝环固定包扎是一种简单有效的包扎固定方法,可以提高活动大的部位白癜风手术治疗的成功率。